AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.

Also called NCT03317002

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 129 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03317002
Other papers using this trial's data
  • Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study International journal of cardiology, 2022-10-15 DOI, PubMed 35842004

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Denmark, Finland, Sweden (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03317002. Randomized; triple masking; primary purpose treatment. Start 2017-10-30 (actual); primary completion 2020-04-08 (actual). Results posted on 2021-06-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).
Acronym
FLAVOUR
Intervention (Drug)
AZD5718
Intervention (Drug)
AZD5718
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct03317002
Content hash
d21e14eedf3c7aecbd3379fc6b6b90261180aa557b54fe550b89fa37de6b54a2